Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Novavax ( (NVAX) ) has provided an announcement.
On June 20, 2025, Novavax, Inc. held its Annual Meeting where stockholders voted on several key proposals. The election of three Class III directors, approval of executive compensation, and ratification of Ernst & Young LLP as the independent auditor were all passed, indicating strong shareholder support for the company’s current management and strategic direction.
The most recent analyst rating on (NVAX) stock is a Sell with a $8.00 price target. To see the full list of analyst forecasts on Novavax stock, see the NVAX Stock Forecast page.
Spark’s Take on NVAX Stock
According to Spark, TipRanks’ AI Analyst, NVAX is a Neutral.
Novavax’s overall score is primarily driven by promising revenue growth and recent strategic corporate events, including FDA approval and positive trial results. However, financial instability due to high leverage and negative cash flows, along with bearish technical indicators, pose significant risks. The stock’s undervaluation and positive earnings call sentiment provide a counterbalance, suggesting potential for future growth if financial stability is improved.
To see Spark’s full report on NVAX stock, click here.
More about Novavax
Novavax, Inc. operates in the biotechnology industry, focusing on the development and commercialization of vaccines to prevent serious infectious diseases.
Average Trading Volume: 8,870,930
Technical Sentiment Signal: Sell
Current Market Cap: $1.04B
Learn more about NVAX stock on TipRanks’ Stock Analysis page.